Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Tesamorelin (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 14 Oct 2019 Results presented in a Theratechnologies media release.
- 11 Oct 2019 Results presened in a Theratechnologies Media Release.
- 11 Oct 2019 According to a Theratechnologies media release, results were published in the Lancet HIV.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History